# Surviving Sepsis ··· Campaign •

SURVIVING SEPSIS CAMPAIGN: GUIDELINES ON THE MANAGEMENT OF CRITICALLY ILL ADULTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)

## **VENTILATION RECOMMENDATIONS TABLE**

#### **VENTILATORY SUPPORT**

RECOMMENDATION #23	STRENGTH & QUALITY OF EVIDENCE
In adults with COVID-19, we <b>suggest</b> starting supplemental oxygen if the peripheral oxygen saturation (Spo2) is < 92%, and <b>recommend</b> starting supplemental oxygen if Spo2 is < 90%.	<ul><li>Strong</li><li>Moderate-Quality of Evidence</li></ul>
RECOMMENDATION #24	STRENGTH & QUALITY OF EVIDENCE
In adults with COVID-19 and <b>acute hypoxemic respiratory failure</b> <b>on oxygen</b> , we <b>recommend</b> that Spo2 be maintained no higher than 96% (strong recommendation, moderate quality evidence).	<ul><li>Strong</li><li>Moderate-Quality of Evidence</li></ul>
RECOMMENDATION #25	STRENGTH & QUALITY OF EVIDENCE
For the <b>acute resuscitation</b> of adults with COVID-19 and shock, we <b>recommend</b> using crystalloids over unbalanced crystalloids.	<ul><li>Weak</li><li>Low-Quality of Evidence</li></ul>
RECOMMENDATION #26	STRENGTH &
	QUALITY OF EVIDENCE
For the <b>acute resuscitation</b> of adults with COVID-19 and shock, we <b>suggest</b> using buffered/ balanced crystalloids over unbalanced crystalloids.	<ul><li>Weak</li><li>Low-Quality of Evidence</li></ul>



RECOMMENDATION #27	STRENGTH & QUALITY OF EVIDENCE
In adults with COVID-19 and acute hypoxemic respiratory failure, if HFNC is not available and there is no urgent indication for endotracheal intubation, we suggest a trial of NIPPV with close monitoring and short-interval assessment for worsening of respiratory failure.	<ul><li>Weak</li><li>Very Low-Quality</li><li>of Evidence</li></ul>
RECOMMENDATION #28	STRENGTH & QUALITY OF EVIDENCE
<i>We were not able to make a recommendation</i> regarding the use of helmet NIPPV compared with mask NIPPV. It is an option, but we are not certain about its safety or efficacy in COVID-19.	
RECOMMENDATION #29	STRENGTH &
	QUALITY OF EVIDENCE
In adults with COVID-19 receiving NIPPV or HFNC, we	Best Practice Statement

**recommend** close monitoring for worsening of respiratory status, and early intubation in a controlled setting if worsening occurs.

## **INVASIVE MECHANICAL VENTILATION**

RECOMMENDATION #30	STRENGTH &
	QUALITY OF EVIDENCE
In mechanically ventilated adults with <b>COVID-19 and ARDS</b> , we <b>recommend</b> using low tidal volume (Vt) ventilation (Vt 4–8mL/kg of predicted body weight), over higher tidal volumes (Vt > 8mL/kg).	<ul><li>Strong</li><li>Moderate-Quality of Evidence</li></ul>

RECOMMENDATION # 31	STRENGTH & QUALITY OF EVIDENCE
For mechanically ventilated adults with <b>COVID-19 and ARDS</b> , we <b>recommend</b> targeting plateau pressures (Pplat) of < 30cm H <sub>2</sub> O.	<ul> <li>Strong</li> <li>Moderate-Quality of Evidence</li> </ul>

## **PRACTICAL CONSIDERATIONS**

Society of Critical Care Medicine

RECOMMENDATION #32	STRENGTH &
For mechanically ventilated adults with <b>COVID-19 and moderate</b> to severe ARDS, we <i>suggest</i> using a higher PEEP strategy, over a lower PEEP strategy (weak recommendation, low-quality evidence). Remark: If using a higher PEEP strategy (i.e., PEEP > 10 cm H <sub>2</sub> O), clinicians should monitor patients for barotrauma.	<ul> <li>Weak</li> <li>Low-Quality of Evidence</li> </ul>
RECOMMENDATION #33	STRENGTH & QUALITY OF EVIDENCE
For mechanically ventilated adults with <b>COVID-19 and ARDS</b> , we <b>suggest</b> using a conservative fluid strategy over a liberal fluid strategy.	<ul><li>Weak</li><li>Low-Quality of Evidence</li></ul>
RECOMMENDATION #34	STRENGTH & QUALITY OF EVIDENCE
For mechanically ventilated adults with <b>COVID-19 and moderate</b> <b>to severe ARDS</b> , we <i>suggest</i> prone ventilation for 12 to 16 hours, over no prone ventilation.	<ul><li>Weak</li><li>Low-Quality of Evidence</li></ul>
Recommendation #35.1: For mechanically Ventilated patients with COVID-19 and moderate to severe ARDS	STRENGTH & QUALITY OF EVIDENCE
We <b>suggest</b> using, as needed, intermittent boluses of neuromuscular blocking agents (NMBA), over continuous NMBA infusion, to facilitate protective lung ventilation.	<ul><li>Weak</li><li>Low-Quality of Evidence</li></ul>
Recommendation #35.2: For mechanically Ventilated	STRENGTH &
In the event of persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation, or persistently high plateau pressures, we <b>suggest</b> using a continuous NMBA infusion for up to 48 hours.	<ul> <li>QUALITY OF EVIDENCE</li> <li>Weak</li> <li>Low-Quality of Evidence</li> </ul>
RECOMMENDATION #36	STRENGTH &
In mechanically ventilated adults with COVID-19 ARDS, we recommend against the routine use of inhaled nitric oxide.	<ul> <li>Strong</li> <li>Low-Quality of Evidence</li> </ul>

